PD-1/PD-L1-IN-23

PD-1/PD-L1-IN-23

• CAS Number: 2597056-04-5
• UNSPSC Description: PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice[1].
• Target Antigen: PD-1/PD-L1
• Type: Reference compound
• Related Pathways: Immunology/Inflammation
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/pd-1-pd-l1-in-23.html
• Solubility: DMSO : 250 mg/mL (ultrasonic)
• Smiles: ClC1=CC(CN[C@@H](C(OCC)=O)CO)=C(OCC2=CC3=NON=C3C=C2)C=C1OCC4=C(Br)C(C5=CC=CC=C5)=CC=C4.[H]Cl
• Molecular Weight: 703.41
• References & Citations: [1]Liu L, et al. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[c][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with In Vivo Antitumor Activity. J Med Chem. 2021;64(12):8391-8409.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported